June 30, 2017
A Massachusetts federal judge on Friday granted Novartis Pharmaceuticals Corp.'s bid to toss a proposed class action alleging the company participated in an anti-competitive scheme to extend its monopoly on leukemia drug Gleevec.
May 10, 2017
End payors accusing Novartis Pharmaceuticals of violating antitrust laws by filing an invalid patent for leukemia drug Gleevec and starting sham litigation over it shouldn't get to try to lift a stay on fact-finding, the company told a Massachusetts federal court Wednesday.
August 01, 2016
Third-party purchasers of a Novartis leukemia drug told a Massachusetts federal judge Monday that the company lied to patent examiners about how easy it was to come up with the $2 billion-a-year formulation, then violated antitrust law by engaging in "sham" litigation to protect its patent for another eight months.
June 10, 2016
A proposed class of purchasers asked a Massachusetts federal court Thursday to keep alive its antitrust suit over Novartis Pharmaceuticals Corp.'s leukemia drug Gleevec, saying the company's patent application and infringement litigation were shams that violated antitrust laws.
August 21, 2015
A proposed putative class of purchasers pushed back Thursday against arguments by Novartis Pharmaceuticals Corp. that they lack standing to challenge the validity of leukemia drug Gleevec's patent, claiming their focus is actually on the company's alleged antitrust activity.
July 30, 2015
Novartis Pharmaceuticals Corp. told a Massachusetts federal judge to dismiss a proposed class action that claims the company illegally withheld generic versions of a leukemia drug from consumers, saying the plaintiffs lack standing to sue and have failed to state a claim.
June 23, 2015
Novartis Pharmaceuticals Corp. conspired to improperly withhold generic versions of Gleevec — a blockbuster leukemia medication — from the consumer market, two employee welfare funds alleged in a proposed class action filed on Monday in Massachusetts federal court.